For the year ending 2025-12-31, KROS has $338,021K in assets. $34,889K in debts. $287,415K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 287,415 | |||
| Accounts receivable | 3,567 | |||
| Prepaid expenses and other current assets | 22,202 | |||
| Current income tax receivable | 2,250 | |||
| Total current assets | 315,434 | |||
| Operating lease right-of-use assets | 16,841 | |||
| Property and equipment, net | 4,297 | |||
| Restricted cash | 1,449 | |||
| Other long term assets | 0 | |||
| Total assets | 338,021 | |||
| Accounts payable | 1,967 | |||
| Accrued expenses and other current liabilities | 16,039 | |||
| Current portion of operating lease liabilities | 2,408 | |||
| Total current liabilities | 20,414 | |||
| Operating lease liabilities, net of current portion | 14,475 | |||
| Total liabilities | 34,889 | |||
| Common stock, par value of 0.0001 per share 200,000,000 shares authorized as of december31, 2025 and december31, 2024 40,670,466 shares issued and 19,543,706 shares outstanding as of december31, 2025 and 40,554,705 shares issued and outstanding as of december31, 2024 | 4 | |||
| Treasury stock, at cost 21,126,760 and no shares as of december31, 2025 and december31, 2024, respectively | 384,558 | |||
| Additional paid-in capital | 1,169,451 | |||
| Accumulated deficit | -481,765 | |||
| Total stockholders equity | 303,132 | |||
| Total liabilities and stockholders equity | 338,021 | |||
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)